ZL 2102
Alternative Names: ZL2102Latest Information Update: 30 Oct 2021
Price :
$50 *
At a glance
- Originator Sanofi
- Developer ZAI Lab
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Australia
- 28 Apr 2018 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Australia
- 17 Mar 2015 Phase-I clinical trials in Asthma (In volunteers) and Chronic obstructive pulmonary disease (In volunteers) in Australia (unspecified route)